ES2180175T3 - Uso de una sustancia inhibidora para la mejora de la regeneracion neuronal. - Google Patents

Uso de una sustancia inhibidora para la mejora de la regeneracion neuronal.

Info

Publication number
ES2180175T3
ES2180175T3 ES98924307T ES98924307T ES2180175T3 ES 2180175 T3 ES2180175 T3 ES 2180175T3 ES 98924307 T ES98924307 T ES 98924307T ES 98924307 T ES98924307 T ES 98924307T ES 2180175 T3 ES2180175 T3 ES 2180175T3
Authority
ES
Spain
Prior art keywords
improvement
hydroxylase
neuronal regeneration
inhibiting substance
neuronal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98924307T
Other languages
English (en)
Other versions
ES2180175T5 (es
Inventor
H W Prof Dr Muller
Christine Dr Stichel-Gunkel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEURAXO BIOTEC GmbH
Original Assignee
NEURAXO BIOTEC GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8226794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2180175(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NEURAXO BIOTEC GmbH filed Critical NEURAXO BIOTEC GmbH
Application granted granted Critical
Publication of ES2180175T3 publication Critical patent/ES2180175T3/es
Publication of ES2180175T5 publication Critical patent/ES2180175T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

Uso de una sustancia inhibidora seleccionada del grupo formado por anticuerpos contra el colágeno IV, laminina, entactina, sustancias accesorias para la función apropiada, o el ensamblaje de la membrana basal; agentes quelantes del Fe; inhibidores de hidroxilasas de aminoácidos, tales como prolil-4-hidroxilasa, lisina-hidroxilasa; competidores de 2-oxoglutarato; siendo dicha sustancia inhibidora capaz de la prevención o inhibición específica de la formación de membrana basal inducida por una lesión del tejido neuronal para la fabricación de un medicamento para la mejora de la regeneración neuronal.
ES98924307T 1997-05-14 1998-05-13 Uso de una sustancia inhibidora para la mejora de la regeneracion neuronal. Expired - Lifetime ES2180175T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97107846 1997-05-14
EP97107846A EP0878480A1 (en) 1997-05-14 1997-05-14 A method for the improvement of neuronal regeneration

Publications (2)

Publication Number Publication Date
ES2180175T3 true ES2180175T3 (es) 2003-02-01
ES2180175T5 ES2180175T5 (es) 2008-02-01

Family

ID=8226794

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98924307T Expired - Lifetime ES2180175T5 (es) 1997-05-14 1998-05-13 Uso de una sustancia inhibidora para la mejora de la regeneracion neuronal.

Country Status (8)

Country Link
US (3) US20020115598A1 (es)
EP (2) EP0878480A1 (es)
AT (1) ATE224915T1 (es)
AU (1) AU7654298A (es)
DE (1) DE69808281T3 (es)
DK (1) DK0981549T4 (es)
ES (1) ES2180175T5 (es)
WO (1) WO1998051708A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0878480A1 (en) * 1997-05-14 1998-11-18 H.W. Prof. Dr. Müller A method for the improvement of neuronal regeneration
US6200974B1 (en) 1997-10-24 2001-03-13 Zeneca Limited Phenanthroline derivatives
CN102526044A (zh) * 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
CN101664408B (zh) * 2001-12-06 2013-05-01 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
DE10314082A1 (de) * 2003-03-28 2004-10-21 Mcs Micro Carrier Systems Gmbh Biodegradierbares injizierbares Implantat
CA2620685A1 (en) * 2005-09-02 2007-03-08 Neuraxo Biopharmaceuticals Gmbh Pharmaceutical composition comprising an iron chelator
WO2007048846A1 (de) * 2005-10-27 2007-05-03 Neuraxo Biopharmaceuticals Gmbh Verwendung von eisen chelatisierenden verbindungen, zyklisches adenosinmonophosphat erhöhende verbindungen oder kombinationen davon zur behandlung von axonalen läsionen im zns
EP2000134A1 (en) * 2007-06-06 2008-12-10 Neuraxo Biopharmaceuticals GmbH Use of a substance for the improvement of pns lesions
US9649381B2 (en) 2013-11-06 2017-05-16 Wayne State University Transporter protein-coupled nanodevices for targeted drug delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4214000A (en) † 1978-10-30 1980-07-22 Johnson & Johnson Zinc salt of all-trans-retinoic acid for the treatment of acne
DE3002989A1 (de) 1980-01-29 1981-07-30 Hoechst Ag, 6000 Frankfurt Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels
CA1251729A (en) * 1982-05-19 1989-03-28 Steffen Gay In vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
DE3432094A1 (de) 1984-08-31 1986-03-06 Hoechst Ag, 6230 Frankfurt Ester der pyridin-2,4- und -2,5- dicarbonsaeure als arzneimittel zur inhibierung der prolin- und lysinhydroxylase
US5021404A (en) † 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
WO1993019783A1 (en) * 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
JPH06103773A (ja) † 1992-09-16 1994-04-15 Hitachi Ltd 半導体記憶装置
CA2117889A1 (en) * 1993-02-11 1994-08-18 Martin E. Schwab A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
JPH09503790A (ja) * 1993-10-15 1997-04-15 トーマス ジェファーソン ユニバーシティ 核原発ガン遺伝子に向けられたアンチセンス化合物による細胞外マトリクス合成の阻害
JPH09511219A (ja) * 1993-11-08 1997-11-11 ニュー ヨーク ユニバーシティ 神経損傷の治療における神経細胞−グリア細胞間接着分子Ｎｇ−ＣＡＭ
US5567609A (en) * 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions
EP0878480A1 (en) * 1997-05-14 1998-11-18 H.W. Prof. Dr. Müller A method for the improvement of neuronal regeneration

Also Published As

Publication number Publication date
EP0878480A1 (en) 1998-11-18
DE69808281T2 (de) 2003-01-16
DK0981549T4 (da) 2007-10-29
EP0981549A1 (en) 2000-03-01
DK0981549T3 (da) 2003-02-10
EP0981549B1 (en) 2002-09-25
EP0981549B9 (en) 2008-02-27
AU7654298A (en) 1998-12-08
ATE224915T1 (de) 2002-10-15
DE69808281D1 (de) 2002-10-31
EP0981549B2 (en) 2007-06-27
WO1998051708A1 (en) 1998-11-19
DE69808281T3 (de) 2008-01-24
US20050118177A1 (en) 2005-06-02
ES2180175T5 (es) 2008-02-01
US20020115598A1 (en) 2002-08-22
US20070231330A1 (en) 2007-10-04
US7208153B2 (en) 2007-04-24

Similar Documents

Publication Publication Date Title
ES2180175T3 (es) Uso de una sustancia inhibidora para la mejora de la regeneracion neuronal.
NO993935D0 (no) Behandling av infarkter ved inhibering av NF-<Kappa>B
BR0115427A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto
BR0115411A (pt) Combinações sinergìsticas compreendendo um inibidor de renina para doenças cardiovasculares
TR200100004T2 (tr) Bir veya birden fazla etkin bileşen ihtiva eden amin tepkime terkipleri
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
ES2160897T3 (es) Pirazoles como inhibidores de la secretora fosfolipasa a2 humana no pancreatica.
TR199902071T2 (xx) Heterosiklik bile�ikler ve bunlar�n �-amilioid peptidinin inhibisyonunda kullan�m�
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
AR031141A1 (es) Compuestos de c-nitrosoanilina y sus combinaciones como inhibidores de la polimerizacion
DK0934065T3 (da) Hidtil ukendte cruptophycinderivater som antieoplastiske midler
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DK1456380T3 (da) SMAD7-inhibitorer til behandling af CNS-sygdomme
BR0115424A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto
BR9910678A (pt) Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto
BR9713207A (pt) Derivados de 3-mercaptoacetilamino-1,5-substituìdo-2-oxo-azepan uteis como inibidores de metaloproteinase de matriz
EP0916344A3 (en) Nef action inhibitor
EA200100930A1 (ru) Способ лечения хозл
ATE400563T1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
AR031126A1 (es) Acidos amino(oxo)aceticos inhibidores de la proteina tirosina fosfatasa
DE69626544T2 (de) Arzneistoffe
DK1625152T3 (da) Peptider, som modulerer sktiviteten af Engrailed-transskriptionsfaktoren
AP2034A (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.
ES2187666T3 (es) Nicorandil para la neurosis de ansiedad.
AR060186A1 (es) Inhibidores de la prenil-transferasa para el control de la hipertension ocular y el tratamiento del glaucoma